FDA Approves Lucentis Biosimilar Nufymco - Quiz - MDSpire

FDA Approves Lucentis Biosimilar Nufymco

Ranibizumab-leyk (Nufymco) is approved for all Lucentis indications.

By
Conexiant News Staff
January 2, 2026
1 min

Ophthalmology Management

Share

Original Source(s)

Ophthalmology Management

FDA Approves Lucentis Biosimilar Nufymco

by Conexiant News Staff
January 2, 2026

Related Content

Frontiers In Medicine

Anti-Diabetic Retinopathy Molecular Mechanism of Dihuang Yinzi: Insights from Network Pharmacology, Metabolomics, and Microbiome Analysis

by Chai, Jinmiao , Gui, Wanwei , Zhang, Junlong , He, Wenbin , Li, Qinqing
April 28, 2026

Frontiers In Neurology

Distinctive vascular changes in the retina and choroid linked to retrograde flow in the ophthalmic artery due to chronic total occlusion of the carotid artery

by Ling Feng, Xiaofeng Tan, Le Cao, Hang Wang, Yueyue He, William Robert Kwapong, Hong Chen, Bo Wu
April 20, 2026

Jama Ophthalmology

Nonexudative Macular Neovascularization in Age-Related Macular Degeneration